Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

Table 1 Clinical and laboratory variables of studied groups

	Ovarian cancer (n = 30)	Benign gynecological (n = 20)	Controls (n = 20)	p (ANOVA)
Age (range)	24-73	40-60	30-66	-
Menopause%	30	25	20	-
RBCs count x10¹²/l	4.5 ± 0.5	4.5 ±0.49	4.8 ± 0.5	NS
Hb g/dl	12.1 ± 1.5	12.5 ± 1.4	12 ± 1.3	NS
WBCs x10⁹/l	8.1 ± 2.9	6.9 ± 2.3	7.6 ± 2	NS
Platelets x10⁹/l	270 ± 82	294.7 ± 72.1	264.7 ± 59.4	NS
S.glucose (mg/dl)	95 ± 15.4	91 ± 7.4	85 ± 9.4	NS
S.urea (mg/dl)	31.4 ± 8.9	29.1 ± 6.7	27.9 ± 7.9	NS
S.creatinine (mg/dl)	0.7 ± 0.15	0.7 ± 0.13	0.73 ± 0.12	NS
ALT (U/l)	17.4 ± 12.6	15.4 ± 11.5	13.9 ± 7.2	NS
AST (U/l)	24.7 ± 14.5	21.1 ± 10.4	21.1 ± 6.1	NS
ALP (U/l)	76.4 ± 24.2	68.5 ± 10.9	70.5 ± 11.3	NS
Total protein g/dl	7.6 ± 0.6	7.4 ± 0.5	7.7 ± 0.53	NS
Albumin g/dl	3.8 ± 0.33	3.9 ± 0.36	3.9 ± 0.29	NS
Total bilirubin mg/dl	0.46 ± 0.3	0.6 ± 0.26	0.5 ± 0.24	NS
D. bilirubin mg/dl	0.12 ± 0.07	0.11 ± 0.06	0.1 ± 0.06	NS
CA125 U/ml	295.5 (4.2-1781)^b,c	26.9 (9.4-553)^a	12.5 (4.1-34.3)	<0.001
HE4 pmol/l	237.2 (34.3-4090)^b,c	66.1 (24.8-179.2)	56.9 (20.8-111.6)	<0.001

Values are expressed as the mean ± standard deviation or median (range). ^aP < 0.05, ^bP < 0.001,with respect to the control group; ^cP = 0.001, with respect to benign gynecological dis.

ISSN: 1746-1596